BARD1 announces positive results from ovarian cancer test
BARD1 Life Sciences Limited (ASX:BD1), a biotechnology company developing non-invasive cancer diagnostics, yesterday informed the market it has received positive results from its OC-400 Study that showed BARD1-Ovarian achieved high accuracy for detection of ovarian cancer.
The encouraging results included an average AUC (area under the curve) of 0.92 in the training sets, and an average AUC of 0.88, 82 per cent sensitivity and 79 per cent specificity in the test sets.
BARD1 has now successfully completed the retrospective, case-control, OC-400 Study which was intended to evaluate the accuracy of the multi-analyte BARD1-Ovarian test to detect ovarian cancer in 400 female bio-banked samples of ovarian cancer and aged-matched healthy controls.
The specific objective of the company’s latest study was to further improve the BARD1 panel and algorithm used in the BARD1-Ovarian, a test which the company hopes will be used for early detection of ovarian cancer. Further, the study assessed the accuracy of the test using the proof-of-concept (POC) method on a panel of 20 peptides (analytes).
All in all, the study determined that BARD1-Ovarian accurately detected ovarian cancer and thereby provides BARD1 with further rationale for developing it into a commercial early detection test.
It should be noted that BARD1 is in its early stages here and investors should seek professional financial advice if considering this stock for their portfolio.
Data analysis of the results produced a model with:
- an average AUC of 0.92, 90% sensitivity and 85% specificity in the training sets, and
- an average AUC of 0.88, 82% sensitivity and 79% specificity in the cross-validation test sets.
The table below provides a summary of the results of BARD1-Ovarian in the OC-400 Study:
These findings support what the company determined via previous studies — that BARD1-Ovarian could detect ovarian cancer “with high sensitivity and specificity”.
Considering ovarian cancer is the eighth most common cancer and the sixth most common cause of cancer death affecting women in Australia, this is a significant finding, particularly for a small-cap biotech company such as BARD1.
In further positive news, the most recent test results were achieved using less analytes, reducing the complexity and cost of the BARD1-Ovarian test — which could bode well for it when compared with the CA125 blood test routinely used as a diagnostic aid for ovarian cancer.
The study concluded that BARD1-Ovarian accurately discriminated ovarian cancer from healthy controls using the POC method and a 20-analyte panel, could detect all subtypes and stages of ovarian cancer, and confirmed the potential of the research-grade test to be further developed into a commercial test with expected high sensitivity and specificity for early detection of ovarian cancer.
BARD1 Executive Director and CSO, Dr Irmgard Irminger-Finger, said “this study showed that using the POC method, BARD1-Ovarian achieved better sensitivity and specificity in a sample set from multiple- sites with a reduced number of analytes than previously reported in the OC-300 Study.”
“The positive results achieved in this OC-400 Study confirmed the potential of BARD1-Ovarian to accurately detect ovarian cancer with high sensitivity and specificity,” BARD1 CEO Dr Leearne Hinch said.
“The reduced analyte panel is an important step forward in the development of an accurate and affordable BARD1-Ovarian test for early detection of ovarian cancer.”
BARD1 intends to advance the development of BARD1-Ovarian, with the potential for outsourcing further assay development to a contract development organisation, in readiness to build it into a commercial test.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.